Hims & Hers Health (NYSE:HIMS) Shares Gap Down Following Insider Selling

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) gapped down prior to trading on Monday after an insider sold shares in the company. The stock had previously closed at $26.56, but opened at $25.54. Hims & Hers Health shares last traded at $25.13, with a volume of 2,446,829 shares changing hands.

Specifically, insider Michael Chi sold 17,303 shares of the stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $27.97, for a total transaction of $483,964.91. Following the transaction, the insider now owns 193,601 shares in the company, valued at approximately $5,415,019.97. This trade represents a 8.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Oluyemi Okupe sold 4,213 shares of the business’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $29.98, for a total transaction of $126,305.74. Following the completion of the sale, the chief financial officer now directly owns 128,365 shares of the company’s stock, valued at approximately $3,848,382.70. The trade was a 3.18 % decrease in their position. The disclosure for this sale can be found here.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of recent research reports. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price objective for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group upped their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. Morgan Stanley assumed coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target for the company. Finally, TD Cowen reissued a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and an average price target of $22.80.

Hims & Hers Health Stock Down 5.4 %

The firm has a 50 day moving average of $26.37 and a 200 day moving average of $21.47. The firm has a market cap of $5.49 billion, a price-to-earnings ratio of 57.11 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same period in the previous year, the company posted ($0.04) EPS. The firm’s revenue was up 77.1% compared to the same quarter last year. Equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of HIMS. Renaissance Technologies LLC raised its stake in shares of Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after purchasing an additional 3,205,108 shares during the last quarter. State Street Corp raised its position in Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after buying an additional 206,078 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after acquiring an additional 482,177 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after acquiring an additional 883,230 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Hims & Hers Health by 15.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock valued at $30,714,000 after purchasing an additional 218,566 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.